{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-133770","form_type":"8-K","ticker":"VRDN","cik":"0001590750","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.120001+00:00","generated_at":"2026-06-02T10:02:55.231656+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Viridian Therapeutics Q1: THRIVE TED trial enrollment completed (113 pts); topline data Sept 2024","bullets":["Cash, cash equivalents, and short-term investments of $613.2M as of March 31, 2024, sufficient into H2 2026.","Net loss of $48.5M for Q1 2024, compared to $68.2M in Q1 2023.","THRIVE global phase 3 trial in active TED enrolled 113 patients (exceeded target of 90); topline data expected September 2024.","Positive FDA Type C meeting for VRDN-003 subcutaneous candidate; pivotal program on track to start mid-2024.","VRDN-006 FcRn inhibitor IND submission on track for year-end 2024; VRDN-008 NHP data expected H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-133770","json":"https://secwatch.observer/filing/0001193125-24-133770.json","markdown":"https://secwatch.observer/filing/0001193125-24-133770.md","text":"https://secwatch.observer/filing/0001193125-24-133770.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590750/000119312524133770/0001193125-24-133770-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590750/000119312524133770/d823086d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T10:02:55.231656+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0d0a0b3a292669c72d1d713741baa27e7388fa42","claim":"Viridian Therapeutics, Inc.\\DE reported first quarter ended March 31, 2024 results: net income $48.5 million.","evidence_excerpt":"The company’s net loss was $48.5 million for the first quarter ended March 31, 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312524133770/0001193125-24-133770-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Net income","value":"$48.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}